ArticlePloS one2025
Risk of cardiovascular mortality in patients with gastric cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the excess cardiovascular disease (CVD) mortality risk in patients with gastric cancer (GC) compared with the general population.
methodsUsing data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program, we conducted a retrospective, population-based cohort study of 41,083 GC patients ≥30 years old between January 1, 1990, and December 31, 2021. A reference cohort from the corresponding general population was also included. Incidence rate ratios (IRRs) for CVD mortality were estimated using Poisson regression.
resultsGC patients were associated with a higher risk of CVD mortality relative to the general population (IRR: 1.46; 95% CI: 1.40-1.52). The relative risk was highest among younger patients aged 30-39 years (IRR: 7.69; 95% CI: 2.48-23.86). Cardiovascular mortality risk peaked during the first month after cancer diagnosis (IRR: 11.52; 95% CI: 9.97-13.31). The relationship between GC and CVD mortality varied according to demographic and clinical characteristics.
conclusionsThese population-based findings support early cardiac assessment and comprehensive risk stratification in GC care. Prospective studies with richer confounder data are needed to test whether these strategies improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.